Here, we demonstrated that BBT-877, a novel inhibitor of ATX, attenuates DN in type 1 diabetic mice by lowering systemic blood glucose levels as well as suppressing the expression of pro-inflammatory cytokines and fibrotic factors in the kidney. Here, ENPP2 is linked to type 1 diabetes mellitus.